The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):: a randomised trial

被引：0

作者：

Lechat, P ^{[1
]}

Brunhuber, KW ^{[1
]}

Hofmann, R ^{[1
]}

Kühn, P ^{[1
]}

Nesser, HJ ^{[1
]}

Slany, J ^{[1
]}

Weihs, W ^{[1
]}

Wiedermann, C ^{[1
]}

Wimmer, H ^{[1
]}

van Mieghem, W ^{[1
]}

Boland, J ^{[1
]}

Chaudron, JM ^{[1
]}

Jordaens, L ^{[1
]}

Melchior, JP ^{[1
]}

Aschermann, M ^{[1
]}

Bruthansl, J ^{[1
]}

Hradec, M ^{[1
]}

Kölbel, F ^{[1
]}

Semrád, B ^{[1
]}

Haghfelt, T ^{[1
]}

Fischer-Hansen, J ^{[1
]}

Goetzsche, CO ^{[1
]}

Hildebrandt, P ^{[1
]}

Kassis, E ^{[1
]}

Rasmussen, V ^{[1
]}

Rokkedal, J ^{[1
]}

Thomassen, A ^{[1
]}

Groundstroem, K ^{[1
]}

Uusimaa, P ^{[1
]}

Le Heuzey, JY ^{[1
]}

Aumont, MC ^{[1
]}

Aupetit, JF ^{[1
]}

Baille, N ^{[1
]}

Baudouy, P ^{[1
]}

Belin, A ^{[1
]}

Bonneau, A ^{[1
]}

Bonneric, G ^{[1
]}

Bousser, JP ^{[1
]}

Citron, B ^{[1
]}

Dary, P ^{[1
]}

Decoulx, E ^{[1
]}

De Groote, P ^{[1
]}

Denolle, T ^{[1
]}

Dievart, F ^{[1
]}

Duriez, P ^{[1
]}

Eicher, JC ^{[1
]}

Enjuto, G ^{[1
]}

Ferrière, M ^{[1
]}

Fournier, E ^{[1
]}

Garandeau, M ^{[1
]}

机构：

[1] Hop La Pitie Salpetriere, AP HP, Dept Pharmacol, F-75013 Paris, France

来源：

LANCET | 1999年 / 353卷 / 9146期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background In patients with heart failure, beta-blochade has improved morbidity and left-ventricular function, but the impact on survival is uncertain. We investigated the efficacy of bisoprolol, a beta(1) selective adrenoceptor blocker in decreasing all-cause mortality in chronic heart failure. Methods In a multicentre double-blind randomised placebo-controlled trial in Europe, we enrolled 2647 symptomatic patients in New York Heart Association class III or IV, with left-ventricular ejection fraction of 35% or less receiving standard therapy with diuretics and inhibitors of angiotensin-converting enzyme. We randomly assigned patients bisoprolol 1.25 mg (n=1327) or placebo (n=1320) daily, the drug being progressively increased to a maximum of 10 mg per day. Patients were followed up for a mean of 1.3 years. Analysis was by intention to treat. Findings CIBIS-II was stopped early, after the second interim analysis, because bisoprolol showed a significant mortality benefit. All-cause mortality was significantly lower with bisoprolol than on placebo (156 [11.8%] vs 228 [17.3%] deaths with a hazard ratio of 0.66 (95% CI 0.54-0.81, p<0.0001). There were significantly fewer sudden deaths among patients on bisoprolol than in those on placebo (48 [3.6%] vs 83 [6.3%] deaths), with a hazard ratio of 0.56 (0.39-0.80, p=0.0011). Treatment effects were independent of the severity or cause of heart failure. Interpretation beta-blocker therapy had benefits for survival in stable heart-failure patients. Results should not, however, be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients.

引用

页码：9 / 13

页数：5

共 50 条

[21] Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II)
Simon, T
Mary-Krause, M
Funck-Brentano, C
Lechat, P
Jaillon, P
EUROPEAN HEART JOURNAL, 2003, 24 (06) : 554 - 561
[22] Beta-blockers improve survival in patients with heart failure regardless of renal function. An analysis of the Cardiac Insufficiency BIsoprolol Study II (CIBIS II) trial
Castagno, D.
Jhund, P. S.
Mcmurray, J. J. V.
Erdmann, E.
Zannad, F.
Remme, W. J.
Lopez Sendon, J. L.
Lechat, P.
Dargie, H. J.
EUROPEAN HEART JOURNAL, 2009, 30 : 421 - 421
[23] Female gender is an independent predictor of survival in patients with chronic heart failure: Results from the cardiac insufficiency bisoprolol study (CIBIS II)
Simon, T
Mary-Krause, M
Funck-Brentano, C
Jaillon, P
CIRCULATION, 1999, 100 (18) : 297 - 297
[24] A RANDOMIZED TRIAL OF BETA-BLOCKADE IN HEART-FAILURE - THE CARDIAC-INSUFFICIENCY BISOPROLOL STUDY (CIBIS)
LECHAT, P
JAILLON, P
FONTAINE, ML
CHANTON, E
MESENGE, C
GAGEY, S
GUILLARDEAU, A
DUSSOUS, V
CIRCULATION, 1994, 90 (04) : 1765 - 1773
[25] Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS)
Lechat, P
Escolano, S
Golmard, JL
Lardoux, H
Witchitz, S
Henneman, JA
Maisch, B
Hetzel, M
Jaillon, P
Boissel, JP
Mallet, A
CIRCULATION, 1997, 96 (07) : 2197 - 2205
[26] Determinants of Change in Quality of Life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD)
Scherer, Martin
Duengen, Hans-Dirk
Inkrot, Simone
Tahirovic, Elvis
Lashki, Diana Jahandar
Apostolovic, Svetlana
Edelmann, Frank
Wachter, Rolf
Loncar, Goran
Haverkamp, Wilhelm
Neskovic, Aleksandar
Herrmann-Lingen, Christoph
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2013, 24 (04) : 333 - 338
[27] Cost Effectiveness of Bisoprolol in the Treatment of Chronic Congestive Heart Failure in SwedenAnalysis Using Data from the Cardiac Insufficiency Bisoprolol Study II Trial
Mattias Ekman
Niklas Zethraeus
Bengt Jönsson
PharmacoEconomics, 2001, 19 : 901 - 916
[28] Regional differences between female populations from The Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS ELD)
Duengen, H-D.
Musial-Bright, L.
Tahirovic, E.
Inkrot, S.
Stanojevic, D.
Salinger-Martinovic, S.
Jankovic-Tomasevic, R.
Haverkamp, W.
Gelbrich, G.
Apostolovic, S.
EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S270 - S270
[29] Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2)
Funck-Brentano, C
Lancar, R
Hansen, S
Hohnloser, SH
Vanoli, E
AMERICAN HEART JOURNAL, 2001, 142 (06) : 989 - 997
[30] Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden -: Analysis using data from the cardiac insufficiency bisoprolol study II trial
Ekman, M
Zethraeus, N
Jönsson, B
PHARMACOECONOMICS, 2001, 19 (09) : 901 - 916

← 1 2 3 4 5 →